Cartesian Therapeutics Announces New Employment Inducement Grants

Rhea-AI Summary

Cartesian Therapeutics (NASDAQ: RNAC) granted inducement stock options to two new employees on April 1, 2026. The awards total 52,450 options with an exercise price of $6.39, equal to the closing Nasdaq price that day. Options vest 25% on April 1, 2027, then monthly over 36 months, fully vesting April 1, 2030, and carry a ten-year term. Grants were approved by the board and made under the company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan pursuant to Nasdaq Rule 5635(c)(4).

AI-generated analysis. Not financial advice.

News Market Reaction – RNAC

-2.03%

1 alert

-2.03% News Effect

On the day this news was published, RNAC declined 2.03%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Inducement options: 52,450 options Exercise price: $6.39 per share Initial vesting: 25% +5 more

8 metrics

Inducement options 52,450 options Aggregate options granted to two new employees on Apr 1, 2026

Exercise price $6.39 per share Grant price equal to Nasdaq closing price on Apr 1, 2026

Initial vesting 25% Vesting cliff on April 1, 2027

Full vesting date April 1, 2030 Options fully vested by this date

Option term 10 years Contractual life of inducement options

Market cap $163,030,498 Equity value before this news

52-week high $15.57 52-week high price for RNAC

Year-end cash $126.9M Cash as of Dec 31, 2025, per recent earnings update

Market Reality Check

Price: $7.38 Vol: Volume 103,928 vs 20-day ...

low vol

$7.38 Last Close

Volume Volume 103,928 vs 20-day average 303,547 (about one-third of typical activity) before this news. low

Technical Shares at $6.39 were trading below the 200-day MA of $8.91 and well under the $15.57 52-week high.

Peers on Argus

Peers showed mixed moves with some gains (e.g., AVIR, OMER, NMRA) and a decline ...

1 Up 1 Down

Peers showed mixed moves with some gains (e.g., AVIR, OMER, NMRA) and a decline in DBVT, while RNAC traded at $6.39, suggesting this inducement grant is stock-specific rather than part of a broad sector rotation.

Historical Context

5 past events · Latest: Mar 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 09	Earnings and update	Positive	+31.7%	Year-end 2025 cash runway and multi-trial progress for Descartes-08.
Feb 23	Investor conferences	Neutral	+0.7%	Announcement of participation in multiple healthcare investor conferences.
Feb 03	Inducement grants	Neutral	+2.1%	12,050 stock options granted to new employees as inducement awards.
Jan 09	Pipeline outlook	Positive	+1.0%	Progress on AURORA, TRITON, HELIOS trials and durable response data.
Jan 06	Inducement grants	Neutral	+1.9%	7,350 stock options granted to two new employees under inducement plan.

Pattern Detected

Recent news, including earnings and prior inducement grants, has typically been followed by modestly positive price reactions.

Recent Company History

Over recent months, Cartesian reported full-year 2025 results with $126.9M cash and runway into mid-2027, alongside progress across AURORA, TRITON and HELIOS trials, which coincided with a 31.68% gain. It has repeatedly used small employment inducement option grants in January, February, and now April 2026, each followed by low-single-digit gains. Conference participation and pipeline progress updates round out a steady cadence of clinical and corporate milestones into early 2026.

Market Pulse Summary

This announcement details a routine employment inducement grant of 52,450 stock options at an exerci...

Analysis

This announcement details a routine employment inducement grant of 52,450 stock options at an exercise price of $6.39, vesting over four years and expiring after 10 years. It follows earlier 2026 inducement grants with similar structures, reinforcing an ongoing hiring and retention strategy. Investors may contextualize this against RNAC’s position below its 200-day MA of $8.91 and the company’s previously disclosed cash runway into mid-2027 and late-stage clinical pipeline progress.

Key Terms

nasdaq global market, amended and restated 2018 employment inducement incentive award plan, nasdaq listing rules

3 terms

nasdaq global market financial

"the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date"

The Nasdaq Global Market is a section of the stock exchange where larger, well-established companies are listed and publicly traded. It functions like a marketplace where investors can buy and sell shares of these companies, providing them with access to capital and opportunities for growth. Its role is important because it helps investors identify and invest in reputable companies with strong financial backgrounds.

amended and restated 2018 employment inducement incentive award plan financial

"The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan"

A plan that lays out stock or cash rewards given to new employees as a recruiting or retention tool, originally created in 2018 and then formally updated and rewritten to replace the prior rules. Investors care because such plans change how many shares or payments a company may grant, which can dilute existing shareholders, increase compensation expense, and signal how management intends to attract or keep key staff—like a revised hiring bonus policy for valuable talent.

nasdaq listing rules regulatory

"The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement"

Nasdaq listing rules are the rulebook a company must follow to have its shares traded on the Nasdaq stock exchange, covering entry requirements and ongoing standards for finances, corporate governance, public disclosure and reporting. For investors they matter because the rules create baseline checks — like a driver’s license and regular inspections for a car — that promote transparency, comparability and reduce the risk of fraud or sudden delisting.

AI-generated analysis. Not financial advice.

FREDERICK, Md., April 02, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to two new employees. On April 1, 2026, the Company issued to these employees options to purchase an aggregate of 52,450 shares of the Company’s common stock with an exercise price of $6.39, the closing trading price of the Company’s common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company’s board of directors. The options vest as to 25% on April 1, 2027, and then in thirty-six substantially equal monthly installments thereafter such that the options will be fully vested on April 1, 2030. The options have a ten-year term. The options were granted under Rule 5635(c)(4) of the Nasdaq Listing Rules as an inducement material to the employees’ entry into employment with the Company.

About Cartesian Therapeutics

Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis and in Phase 1/2 clinical development of juvenile dermatomyositis with plans to initiate a Phase 2 trial in myositis, specifically dermatomyositis and antisynthetase syndrome in the first half of 2026. For more information, please visit www.cartesiantherapeutics.com or follow the Company on LinkedIn or X.

Contact Information:
Investor Contact:
Megan LeDuc
Associate Director, Investor Relations
megan.leduc@cartesiantx.com

Media Contact:
David Rosen
Argot Partners
david.rosen@argotpartners.com 

FAQ

What stock awards did Cartesian Therapeutics (RNAC) grant on April 1, 2026?

They granted options to purchase an aggregate of 52,450 shares with an exercise price of $6.39. According to the company, grants were issued under its inducement award plan and approved by the board.

What is the vesting schedule for the RNAC inducement options granted April 1, 2026?

Options vest 25% on April 1, 2027, then monthly over 36 equal installments, fully vesting on April 1, 2030. According to the company, this schedule aligns with standard multi-year retention terms.

What exercise price and term apply to the RNAC inducement options dated April 1, 2026?

The exercise price is $6.39, the closing Nasdaq price on the grant date, and each option has a ten-year term. According to the company, the price equals the market close on April 1, 2026.

Under what authority were the RNAC inducement awards granted to new employees?

The grants were issued under the company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and Nasdaq Rule 5635(c)(4). According to the company, the board approved the awards as inducements to employment.

How many employees received inducement awards from Cartesian Therapeutics on April 1, 2026?

Two new employees received inducement option awards totaling 52,450 options. According to the company, the awards were specifically granted as inducements to the individuals' entry into employment.